Lynn Stockwell - Sep 26, 2025 Form 4 Insider Report for Drugs Made In America Acquisition II Corp. (DMII)

Role
CEO and Exe. Chair of Board, Director, 10%+ Owner
Signature
/s/ Lynn Stockwell
Stock symbol
DMII
Transactions as of
Sep 26, 2025
Transactions value $
$0
Form type
4
Date filed
10/1/2025, 10:40 AM
Previous filing
Sep 24, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Stockwell Lynn CEO and Exe. Chair of Board, Director, 10%+ Owner C/O DRUGS MADE IN AMERICA ACQU. II CORP., 1 EAST BROWARD BOULEVARD, SUITE 700, FORT LAUDERDALE /s/ Lynn Stockwell 2025-10-01 0001927032

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DMII Ordinary shares Purchase +700K +4.87% 15.1M Sep 26, 2025 See Footnote F1
transaction DMII Ordinary shares Other -400K -2.65% 14.7M Sep 26, 2025 See Footnote F1, F2
transaction DMII Ordinary shares Sale -7.97M -54.29% 6.71M Sep 26, 2025 See Footnote F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DMII Rights to receive ordinary shares Purchase +700K 700K Sep 26, 2025 Ordinary shares 70K See Footnote F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects 700,000 private units acquired by Drugs Made In America Acquisition II LLC, the Issuer's sponsor. Each private unit consists of one ordinary share and one right to receive one-tenth (1/10) of an ordinary share upon the consummation of an initial business combination. The private units were purchased at $10 per unit for an aggregate purchase price of $7,000,000. Lynn Stockwell is the managing member of the sponsor and has voting and dispositive power over the securities held of record by the sponsor. Ms. Stockwell disclaims any beneficial ownership of the securities held by the sponsor, except to the extent of her pecuniary interest therein.
F2 As of the Transaction Date, the sponsor transferred an aggregate of 400,000 ordinary shares to certain of the Issuer's officers and directors for no consideration.
F3 As of the Transaction Date, pursuant to share transfer agreements, the sponsor transferred an aggregate of 7,966,667 ordinary shares to a number of accredited investors for consideration ranging from no consideration to $1.50 per share.
F4 The rights convert automatically into ordinary shares at the completion of the Issuer's initial business combination.